NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis

• Published in: BMC immunology 2024-07, Vol.25 (1), p.40-9, Article 40
• Main Authors: Kamel, Fatma Z, Hoseiny, Heba Allah Mohamed, Shahawy, Aya A El, Boghdadi, Ghada, Shahawy, Alia A El
• Format: Article
• Language: English
• Subjects: Adalimumab; Adalimumab - therapeutic use; Adult; Alleles; Biological agents; Biomarkers; Biomarkers - blood; C-Reactive Protein - metabolism; Disease susceptibility; Drug dosages; Drug therapy; Ethylenediaminetetraacetic acid; Female; Gene Frequency; Gene polymorphism; Genes; Genetic aspects; Genetic polymorphisms; Genetic Predisposition to Disease; Genetic research; Genotype; Genotype & phenotype; Health aspects; Health risks; Heterozygotes; Humans; Immune system; Immunological research; Immunology; Male; Medical diagnosis; Medical research; Medicine, Experimental; Methotrexate; Methotrexate - therapeutic use; Middle Aged; Minority & ethnic groups; Monoclonal antibodies; Necrosis; NLR Family, Pyrin Domain-Containing 3 Protein - genetics; NLRP3; Patient outcomes; Polymorphism; Polymorphism, Single Nucleotide; Prognosis; Psoriasis; Psoriasis - drug therapy; Psoriasis - genetics; Psoriasis vulgaris; Pyrin protein; Severity of Illness Index; Skin; Statistical analysis; TNF; Treatment Outcome; Tumor necrosis factor; Tumor Necrosis Factor-alpha - genetics; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Tumors
• ISSN: 1471-2172; 1471-2172
• DOI: 10.1186/s12865-024-00630-2

Psoriasis has a global prevalence of 1-3%, with variations observed across different ethnic groups and geographical areas. Disease susceptibility and response to anti-tumor necrosis factor-α (TNFα) drugs suggest different genetic regulatory mechanisms which may include NLR family pyrin domain containing 3 (NLRP3) polymorphism. Evaluation of the NLRP3 gene polymorphism, the serum level of CRP and TNFα in psoriasis patients and assessment of the NLRP3 (rs10754558) gene polymorphism, CRP and TNFα with disease severity and their role as biomarkers for response to Methotrexate and Adalimumab in psoriasis. The study had a total of 75 patients diagnosed with psoriasis vulgaris, who were compared to a control group of 75 healthy individuals. There was a highly significant difference in NLRP3 genotypes and alleles distribution between psoriasis patients and controls (P = 0.002,0.004). The heterozygote genotype GC (OR = 3.67,95%CI:1.75-7.68, P = 0.0006), was linked with increased risk of psoriasis. Additionally, The GC genotype was significantly associated with nonresponse to psoriasis therapy (OR = 11.7,95%CI:3.24-42.28, P = 0.0002). Regarding serum CRP and TNFα levels, there was a highly statistically significant difference between psoriasis patients and controls (P